Karyopharm Therapeutics (NASDAQ:KPTI) PT Raised to $15.00

Share on StockTwits

Karyopharm Therapeutics (NASDAQ:KPTI) had its target price lifted by Wedbush from $11.00 to $15.00 in a report issued on Tuesday morning. The brokerage currently has an outperform rating on the stock. Wedbush also issued estimates for Karyopharm Therapeutics’ Q3 2019 earnings at ($0.82) EPS, Q4 2019 earnings at ($0.83) EPS, FY2019 earnings at ($3.45) EPS, Q1 2020 earnings at ($0.69) EPS, Q2 2020 earnings at ($0.66) EPS, Q3 2020 earnings at ($0.58) EPS, Q4 2020 earnings at ($0.49) EPS, FY2020 earnings at ($2.40) EPS, FY2021 earnings at ($1.39) EPS, FY2022 earnings at ($0.40) EPS and FY2023 earnings at $0.70 EPS.

KPTI has been the subject of several other research reports. Robert W. Baird reaffirmed an outperform rating and issued a $25.00 price target (up previously from $15.00) on shares of Karyopharm Therapeutics in a research report on Friday, July 5th. JPMorgan Chase & Co. raised shares of Karyopharm Therapeutics from a neutral rating to an overweight rating and upped their price target for the stock from $8.00 to $16.00 in a research report on Tuesday, July 23rd. Zacks Investment Research cut shares of Karyopharm Therapeutics from a buy rating to a hold rating in a research report on Saturday, July 13th. BidaskClub raised shares of Karyopharm Therapeutics from a hold rating to a buy rating in a research report on Friday, September 13th. Finally, HC Wainwright reaffirmed a buy rating and issued a $32.00 price target (up previously from $29.00) on shares of Karyopharm Therapeutics in a research report on Friday, July 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Karyopharm Therapeutics currently has a consensus rating of Buy and an average target price of $17.89.

Shares of KPTI opened at $11.32 on Tuesday. The company has a 50 day moving average price of $9.25 and a 200-day moving average price of $6.69. Karyopharm Therapeutics has a fifty-two week low of $3.92 and a fifty-two week high of $19.19. The stock has a market capitalization of $722.61 million, a PE ratio of -3.61 and a beta of 2.41. The company has a debt-to-equity ratio of 1.46, a quick ratio of 6.93 and a current ratio of 6.93.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.26. Karyopharm Therapeutics had a negative net margin of 2,138.80% and a negative return on equity of 154.75%. The firm had revenue of $9.49 million during the quarter. Equities research analysts forecast that Karyopharm Therapeutics will post -3.65 EPS for the current year.

In related news, CEO Michael Kauffman sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $12.00, for a total transaction of $120,000.00. Following the completion of the transaction, the chief executive officer now owns 539,767 shares in the company, valued at approximately $6,477,204. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Sharon Shacham sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $12.00, for a total transaction of $240,000.00. Insiders own 13.26% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Envestnet Asset Management Inc. raised its stake in shares of Karyopharm Therapeutics by 12.4% during the 2nd quarter. Envestnet Asset Management Inc. now owns 11,980 shares of the company’s stock worth $72,000 after acquiring an additional 1,319 shares in the last quarter. DekaBank Deutsche Girozentrale raised its stake in shares of Karyopharm Therapeutics by 20.7% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 19,800 shares of the company’s stock worth $419,000 after acquiring an additional 3,400 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Karyopharm Therapeutics by 8.6% during the 2nd quarter. Wells Fargo & Company MN now owns 60,384 shares of the company’s stock worth $361,000 after acquiring an additional 4,761 shares in the last quarter. Bank of Montreal Can acquired a new position in Karyopharm Therapeutics during the 2nd quarter valued at approximately $29,000. Finally, Swiss National Bank increased its stake in Karyopharm Therapeutics by 6.3% during the 2nd quarter. Swiss National Bank now owns 90,550 shares of the company’s stock valued at $542,000 after purchasing an additional 5,400 shares in the last quarter. Hedge funds and other institutional investors own 82.55% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).

Read More: What is the Coverage Ratio?

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MakeMyTrip Limited  to Post Q2 2020 Earnings of  Per Share, Jefferies Financial Group Forecasts
MakeMyTrip Limited to Post Q2 2020 Earnings of Per Share, Jefferies Financial Group Forecasts
Provident Financial Services  versus Umpqua  Head-To-Head Contrast
Provident Financial Services versus Umpqua Head-To-Head Contrast
Critical Comparison: Sculptor Capital Management  & The Competition
Critical Comparison: Sculptor Capital Management & The Competition
Independent Bank  to Release Quarterly Earnings on Thursday
Independent Bank to Release Quarterly Earnings on Thursday
WNS  Set to Announce Quarterly Earnings on Thursday
WNS Set to Announce Quarterly Earnings on Thursday
Chart Industries  Set to Announce Earnings on Thursday
Chart Industries Set to Announce Earnings on Thursday


© 2006-2019 Ticker Report